CureVac N.V. announced that the European Patent Office (EPO) confirmed the validity of its European patent EP 4 023 755 B1, subject to amendments to specific patent claims. This decision largely dismissed the opposition filed by BioNTech SE, Pfizer Inc., and others in December 2023.
This marks a second positive validity decision from the EPO for CureVac's core mRNA patents. The confirmation further strengthens CureVac's intellectual property position in its ongoing litigation.
An infringement hearing for EP 4 023 755 B1, which will also include EP 3 708 668 B1 (validity confirmed in March 2025), is scheduled for July 1, 2025, before the Regional Court Düsseldorf, Germany.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.